AI Article Synopsis

  • The study aimed to analyze the expression of folate receptor alpha (FRα) in tumor samples from patients with relapsed ovarian cancer who could undergo biopsies.
  • The researchers enrolled 27 heavily pre-treated patients, finding a 71% agreement in FRα levels between older archival samples and fresh biopsies, with mild side effects reported.
  • The results indicated a 22% objective response rate to the treatment, with higher effectiveness seen in patients with elevated FRα levels, affirming that archival tissues can effectively select candidates for clinical trials involving mirvetuximab soravtansine.

Article Abstract

Purpose: To characterize folate receptor alpha (FRα) expression in archival and fresh biopsy tumor samples from relapsed ovarian cancer patients.

Methods: Patients with ovarian tumors amenable to biopsy were eligible to enroll. Eligibility included a minimum requirement of FRα positivity in archival tumor samples (≥25% of cells with ≥2+ staining intensity). Patients received mirvetuximab soravtansine at 6mg/kg once every 3weeks. Core needle biopsies were collected before and after treatment and FRα levels assessed by immunohistochemistry. Descriptive statistics were used to summarize the association between receptor expression and response.

Results: Twenty-seven heavily pre-treated patients were enrolled. Six individuals (22%) did not have evaluable pre-treatment biopsies due to insufficient tumor cells. The concordance of FRα expression in archival and biopsy tissues was 71%, and no major shifts in receptor expression were seen in matched pre- and post-treatment biopsy samples. Adverse events were generally mild (≤grade 2) with keratopathy (48%), fatigue (44%), diarrhea, and blurred vision (each 37%) being the most common treatment-related toxicities. The confirmed objective response rate (ORR) was 22%, including two complete responses and four partial responses. Superior efficacy measures were observed in the subset of patients with the highest FRα levels (ORR, 31%; progression-free survival, 5.4months).

Conclusion: Concordance of FRα expression in biopsy versus archival tumor samples suggests that archival tissue can reliably identify patients with receptor-positive tumors and is appropriate for patient selection in mirvetuximab soravtansine clinical trials. Regardless of the tissue source analyzed, higher FRα expression was associated with greater antitumor activity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893864PMC
http://dx.doi.org/10.1016/j.ygyno.2017.08.015DOI Listing

Publication Analysis

Top Keywords

frα expression
20
expression archival
12
archival tumor
12
mirvetuximab soravtansine
12
tumor samples
12
folate receptor
8
receptor alpha
8
frα
8
alpha frα
8
biopsy samples
8

Similar Publications

can utilize fructose-asparagine (F-Asn) as a source of carbon and nitrogen. This capability has been attributed to five genes in the locus. Previously, we determined that mutations in (deglycase), (kinase), or (transporter) eliminated the ability of to grow on F-Asn, while a mutation in allowed partial growth.

View Article and Find Full Text PDF

Folate receptor α (FRα) autoantibodies (FRAAs) are prevalent in autism spectrum disorder (ASD). FRAAs disrupt folate transport across the blood-brain barrier by binding to the FRα. Thyroid dysfunction is frequently found in children with ASD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!